EMFLAZA

PTC Therapeutics, Inc.🇺🇸 United States

FDA Page

Effective Date: Feb 21, 2023
Approval ID: 31b347d2-f156-4055-9d8f-7cf0df420296
Products: 5 registered
Version: 17

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use EMFLAZA safely and effectively. See full prescribing information for EMFLAZA. EMFLAZA (deflazacort) tablets, for oral use EMFLAZA (deflazacort) oral suspension Initial U.S. Approval: 2017

Quick Stats

Total Products5

Labelers2

Label Sections26

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.